Reclassification of oligoastrocytomas by loss of heterozygosity studies
Open Access
- 17 April 2006
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 119 (1) , 84-90
- https://doi.org/10.1002/ijc.21759
Abstract
Oligoastrocytomas (OAs) are WHO grade II or III tumors composed of a mixture of 2 neoplastic cell types morphologically resembling the cells in oligodendrogliomas and diffuse astrocytomas. Investigations on the genetic profile of OAs may yield important information for their classification and help for their clinical management. We have studied, in 94 OAs (46 WHO grade II and 48 WHO grade III), the patterns of loss of heterozygosity (LOH) of 4 genomic regions: 1p, 19q, 17p and 10q. Results were as follows: LOH 1p was present in 46% of the tumors; LOH 19q in 45%; LOH 17p in 22%; LOH 10q in 16%. LOH 1p and 19q were associated in 32%, other LOH associations were rare (vs. 132 months, p < 0.0001. MRI indicated that tumors without LOH on 1p were often temporal (p < 0.02), and showed signal inhomogeneity on T1 and T2 images (p < 0.02) and contrast enhancement (p < 0.04). Thus, LOH on 1p identifies two subgroups of OAs. OAs without LOH on 1p behave like WHO grade II or III diffuse astrocytomas: they have shorter survival, MRI characteristics implying malignancy and genetic alterations associated with tumor progression. OAs with LOH on 1p, on the other hand, behave like WHO grade II or III oligodendrogliomas with 1p loss: they are associated with longer survival and do not have MRI or genetic alterations associated with malignancy. These findings suggest that the definition of OAs or mixed gliomas could be reshaped in agreement with the genetic information.Keywords
This publication has 29 references indexed in Scilit:
- Two types of chromosome 1p losses with opposite significance in gliomasAnnals of Neurology, 2005
- Olig2 expression, GFAP, p53 and 1p loss analysis contribute to glioma subclassificationNeuropathology and Applied Neurobiology, 2004
- Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumorsInternational Journal of Cancer, 2004
- Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with TemozolomideClinical Cancer Research, 2004
- Association of chromosome 10 losses and negative prognosis in oligoastrocytomasAnnals of Neurology, 2002
- Genetic Signature of Oligoastrocytomas Correlates with Tumor Location and Denotes Distinct Molecular SubsetsThe American Journal of Pathology, 2002
- Identification of the small interstitial deletion at chromosome band 1p34–p35 and its association with poor outcome in oligodendroglial tumorsGenes, Chromosomes and Cancer, 2002
- Tumor formation and inactivation of RIZ1, an Rb-binding member of a nuclear protein–methyltransferase superfamilyGenes & Development, 2001
- A study of loss of heterozygosity at 70 loci in anaplastic astrocytoma and glioblastoma multiforme with implications for tumor evolutionNeuro-Oncology, 1999
- Molecular analysis of chromosomh 1 abnormalities in human gliomas reveals frequent loss of 1p in oligodendroglial tumorsInternational Journal of Cancer, 1994